Latest
Asia-Pacific

‘Pushing food around the plate’: How weight-loss drugs are changing what Australia eats

The first GLP-1 weight-loss tablets arrive in Australia as chefs, supermarkets and fast-food chains rethink portion sizes and menus.

News Line International Staff20 November 2026 at 00:03 UTC2 min read
‘Pushing food around the plate’: How weight-loss drugs are changing what Australia eats

Australia is still at an early stage of the GLP-1 wave, says Rolf Weber, who leads meals-delivery business Marley Spoon. Twelve per cent of Marley Spoon’s sales are “GLP-1 support” meals, which are smaller, low in fat, have at least 20 grams of protein, six grams of fibre, and designed to be easy to digest.

GLP-1 drugs are subsidised through the Pharmaceutical Benefits Scheme (PBS) for type 2 diabetes and cardiovascular disease, but not for weight loss alone. People who want the drug for weight loss must pay hundreds of dollars a month, meaning disadvantaged people are either priced out of the life-changing medication or sacrificing other spending. One study found half a million people each month use it for type 2 diabetes, and more still for weight loss. A separate EY Studio+ survey found one in 10 Australian adults used them.

But regulatory approval of GLP-1 tablets (instead of a weekly injection) and the drug’s expected listing on the PBS for weight-loss purposes (slashing prices to just $25 a month) are tipped to ramp up demand.

“It will become more affordable – that means a higher uptake. It will reach some sort of ceiling eventually, but we’re far away from reaching that,” says Weber. He predicts, in time, 20 per cent of Australians will either be on weight-loss medication or taking a break from it.

“I suspect we may look back on [GLP-1’s] impact on society and say it’s been one of the most significant changes in a long time.”Advertising executive Ben Willee

Consultants EY-Parthenon forecast take-up will rise to 30 per cent in a decade if PBS approval expands to include GLP-1 use for weight loss and secondary morbidities such as hypertension and heart disease. Health Minister Mark Butler has described this class of drugs as “too important” not to have on the PBS, but there are concerns about how much this would cost. A spokesperson for the Department of Health says negotiations on a potential PBS listing for weight management were ongoing.

Next month, a decision will be released on expanding a PBS listing to obese patients with a history of heart attack, stroke or peripheral arterial disease. As yet, no company has sought subsidy through the PBS for weight-loss management alone. PBS listings typically take months, rather than years.

More in Asia-Pacific

All Asia-Pacific »